US 11,986,514 B2
Compositions for treating macular edema
Francine Behar-Cohen, Paris (FR); Raphael Cohen, Paris (FR); Rinath Levy-Boukris, Paris (FR); and Min Zhao, Paris (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LASANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); SORBONNE UNIVERSITE, Paris (FR); UNIVERSITE DE PARIS, Paris (FR); and ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR)
Appl. No. 16/642,642
Filed by INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris (FR); SORBONNE UNIVERSITE, Paris (FR); UNIVERSITE DE PARIS, Paris (FR); and ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR)
PCT Filed Aug. 31, 2018, PCT No. PCT/EP2018/073510
§ 371(c)(1), (2) Date Feb. 27, 2020,
PCT Pub. No. WO2019/043179, PCT Pub. Date Mar. 7, 2019.
Claims priority of application No. 17306133 (EP), filed on Sep. 1, 2017.
Prior Publication US 2020/0254069 A1, Aug. 13, 2020
Int. Cl. A61K 38/38 (2006.01); A61K 31/573 (2006.01); A61K 38/01 (2006.01); A61K 47/36 (2006.01); A61P 27/02 (2006.01)
CPC A61K 38/38 (2013.01) [A61K 38/014 (2013.01); A61K 47/36 (2013.01); A61P 27/02 (2018.01); A61K 31/573 (2013.01)] 4 Claims
 
1. A method of treating macular edema in an individual in need thereof, comprising administering to the individual by intravitreous injection, an oncotic pressure-increasing macromolecule having a molecular weight of 25 kDa or more and which does not recognize VEGF, as the sole active ingredient, wherein the oncotic pressure-increasing macromolecule is a protein macromolecule consisting of gelatin.